Novartis Announces Agreement to Develop Influenza Vaccines

Novartis announced an agreement with Synthetic Genomics Vaccines Inc. to apply “synthetic genomics” technologies to accelerate the production of the influenza seed strains required for vaccine manufacturing.
Euroinvestor